New schizophrenia drug shows promise in large trial
NCT ID NCT02469155
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 32 times
Summary
This study tested a new medicine called ITI-007 in 696 people with schizophrenia who were having a sudden worsening of symptoms. For 6 weeks, some received ITI-007, some a placebo, and some an active comparator. The main goal was to see if ITI-007 reduces symptoms like hallucinations and delusions better than placebo. The results help determine if this drug could be a new treatment option for schizophrenia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site
Little Rock, Arkansas, United States
-
Clinical Site
Springdale, Arkansas, United States
-
Clinical Site
Culver City, California, United States
-
Clinical Site
Lemon Grove, California, United States
-
Clinical Site
Long Beach, California, United States
-
Clinical Site
San Diego, California, United States
-
Clinical Site
North Miami, Florida, United States
-
Clinical Site
Berlin, New Jersey, United States
-
Clinical Site
Marlton, New Jersey, United States
-
Clinical Site
Austin, Texas, United States
-
Clinical Site
Dallas, Texas, United States
Conditions
Explore the condition pages connected to this study.